Tuesday, 23 April 2024


Korea-based Celltrion to supply 342,000 ampoules of infliximab to Brazil for autoimmune diseases treatment

13 January 2023 | News

Celltrion to launch at least one biosimilar medicine per year by 2032

image credit- prnewswire

image credit- prnewswire

Celltrion Healthcare, a South Korean biopharmaceutical company specialising in the development and production of biosimilars and new molecules, has won yet another tender to supply the Ministry of Health in Brazil with infliximab, used to treatment of eight autoimmune diseases, including Rheumatoid Arthritis (RA) and Inflammatory Bowel Disease (IBD). According to Michel Batista , the company's senior business manager in Brazil, the established contract is for the supply of 342,000 vials. 

Biosimilar infliximab is developed and manufactured by Celltrion, Inc. and was the world's first monoclonal antibody biosimilar approved by the European Medicines Agency (EMA). It was approved by the EMA in September 2013 and launched in major European Union (EU) countries in early 2015. The US Food and Drug Administration (FDA) approved the medication in April 2016., and has been approved in over 98 countries (as of May 2022), including the US, Canada, Japan, and across Europe. Recently, the solution was also approved in its subcutaneous version, developed to offer patients greater comfort and autonomy in the treatment of chronic inflammatory diseases.

In addition to the medicine used in the treatment of chronic diseases, the South Korean company has recevied approval from the National Health Surveillance Agency (Anvisa) for the biosimilars rituximab, used in the treatment of non-Hodgkin's lymphoma, and trastuzumab, used in the treatment of breast cancer. And for the next year, there is an estimate of the launch of a new product that will bring even more effectiveness and convenience to patients.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account